Previous 10 | Next 10 |
Phase 2 proof-of-concept study evaluating EQ101 efficacy, safety, tolerability and PK/PD in subjects with alopecia areata over 24 weeks of treatment EQ101 targets IL-2, IL-9, and IL-15, key cytokines known to be upregulated in alopecia areata, and therefore may provide a more ...
Preclinical and translational data supports EQ101 for the treatment of alopecia areata Multi-Cytokine Inhibitors may provide a more selective and potent approach to treatment than direct JAK inhibition A phase 2 study of EQ101 in patients with alopecia areata to be...
Phase 1 study evaluating safety, tolerability and PK/PD after single and multiple ascending doses in healthy volunteers and biological activity in subjects with celiac disease Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel th...
Summary Today, we circle back on Equillium for the first time in a year and a half. The company has several compounds in development, recently disclosed encouraging trial results and also executed a small strategic merger. An investment analysis follows in the paragraphs below...
Results demonstrate the use of selective inhibitors of multiple key cytokines as an effective strategy in treating autoimmune diseases driven by T and NK cells Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to tr...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clinical-stage biotechnology firm Equillium (NASDAQ: EQ ), which focuses on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, released encouraging clinical data regarding itolizumab....
Equillium, Inc. ( NASDAQ: EQ ), a biotech focused on immuno-inflammatory disorders, added ~22% i n the morning hours Tuesday as Street reacted to the company’s interim results from the Type B portion of the EQUALISE study evaluating its lead asset itolizumab in lupus ...
Itolizumab demonstrates clinically meaningful response in highly proteinuric subjects: 5 of 6 (83%) subjects achieved complete or partial response and 4 of 6 (67%) subjects achieved > 80% reduction in urine protein creatinine ratio (UPCR) by week 28 8 of 12 ...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that an abstract was accepted for presentation at ACR Convergence, the annual...
Expected to add $33 million in cash at closing to Equillium’s balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MH...
News, Short Squeeze, Breakout and More Instantly...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the Jone...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...
A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 74.6% to $0.46 on volume of 265,324,361 shares MicroAlgo Inc. (MLGO) rose 669.9% to $12.01 on volume of 183,977,846 shares PROSHARES TRUST (SQQQ) fell 0.7% to $9.86 on volume of 124,114,596 shares Faraday ...